This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Cosmetic Surgery Stocks Keep Stiff Upper Lip

Allergan's biggest business remains eye-care drugs, which represents 47% of first-half sales and were up 24% over the same period last year. Because Allergan is more reliant on products that receive insurance coverage, analysts say its stock shouldn't be as volatile as those of Mentor and Medicis. However, Allergan isn't free from worry or risk.

Gary Nachman of Leerink Swann recently trimmed his third-quarter sales and earnings forecasts because his research on cosmetic-treatment trends "were more disappointing than we expected" both in the U.S. and in Europe. Although he maintains an outperform rating, he reduced his price target from the high $60s to the mid- to high $50s.

"We remain confident that Allergan can absorb the potential weaknesses in the aesthetic products with solid diversification and financial flexibility," he says in a recent research report. He doesn't own shares.

The diversification includes the obesity-control device Lap-Band, an adjustable clamp that reduces the amount of food the stomach can hold. First-half 2008 sales of $148.5 million represented a 22% gain from last year.

Additionally, Allergan is testing Botox for new uses such as treating overactive bladder and headaches. Botox started as a drug for a rare condition of uncontrolled eye-blinking.

Meanwhile, investors in Medicis were no doubt blinking on Sept. 24 when the company said an accounting error would force a restatement of five years of financial results. The restatement is not expected to affect cash flows and cash balances, Medicis said. The company also withdrew its financial guidance for the rest of the year. The stock is down about 34% since the day before the restatement announcement.

Stock quotes in this article: AGN, MNT, MRX 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs